Anakinra vs. Steroids for Gout Attacks in patients with Renal Disease

  • Research type

    Research Study

  • Full title

    A Randomised Controlled Trial of Anakinra vs. Steroids for Gout Attacks in patients with Chronic Renal Disease (ASGARD): a Feasibility study

  • IRAS ID

    160630

  • Contact name

    Gowrie Balasubramaniam

  • Contact email

    g.balasubramaniam@southend.nhs.uk

  • Sponsor organisation

    Southend University Hospital

  • Eudract number

    2015-001787-19

  • Clinicaltrials.gov Identifier

    NCT02578394

  • Duration of Study in the UK

    1 years, 10 months, 0 days

  • Research summary

    Gout is a common condition that affects 1 in 40 people in the UK. It causes very painful "attacks" of joint swelling, redness and tenderness, mostly affecting the foot, ankle, knee, hand and wrist. It is very common in people with kidney disease, who also tend to be older people with other medical conditions such as high blood pressure, heart disease and diabetes. We do not know the safest and best way to treat an attack of gout in these patients. A lot of people are given treatment that can worsen their kidney disease, along with their other medical conditions.

    We want to compare the safest treatment currently available, steroids, with a new treatment that is being increasingly used called Anakinra. This treatment stops the action of a chemical called interleukin-1 which has been discovered to play an important role in the acute gout attack. This treatment has already been used in a handful of patients with kidney disease. We feel it may be a better alternative to steroid treatment which can worsen diabetes, and blood pressure if used for a long time. We would like to perform a scientific study comparing these two treatments. This would involve a big expensive study requiring large numbers of patients and large amounts of information to be collected. Before we do a big study like this, we want to perform a small study using smaller numbers of patients. This will then give us information to plan a larger study to answer the question of which treatment may be better, safer and provides the most value for money for the NHS.

  • REC name

    London - Central Research Ethics Committee

  • REC reference

    15/LO/1922

  • Date of REC Opinion

    10 Feb 2016

  • REC opinion

    Further Information Favourable Opinion